Európska únia - holandčina - EMA (European Medicines Agency)

novartis europharm limited  - brolucizumab - natte maculaire degeneratie - ophthalmologica - beovu is geïndiceerd bij volwassenen voor de behandeling van neovascular (natte) leeftijdsgebonden maculaire degeneratie (amd).

Európska únia - holandčina - EMA (European Medicines Agency)

novartis europharm limited  - onasemnogene abeparvovec - spier-atrofie, spinale - andere geneesmiddelen voor aandoeningen van het musculo-skeletale systeem - zolgensma is geïndiceerd voor de behandeling van patiënten met 5q spinale musculaire atrofie (sma) met een bi-allelische mutatie in het smn1-gen en een klinische diagnose sma type 1, orpatients met 5q sma met een bi-allelische mutatie in het smn1-gen en maximaal 3 exemplaren van het smn2 gen.

Európska únia - holandčina - EMA (European Medicines Agency)

novartis europharm limited - indacaterol, glycopyrronium bromide, mometasone - astma - geneesmiddelen voor obstructieve aandoeningen van de luchtwegen, - enerzair breezhaler is indicated as a maintenance treatment of asthma in adult patients not adequately controlled with a maintenance combination of a long acting beta2 agonist and a high dose of an inhaled corticosteroid who experienced one or more asthma exacerbations in the previous year.

Európska únia - holandčina - EMA (European Medicines Agency)

novartis europharm limited  - indacaterol, mometasone furoate - astma - geneesmiddelen voor obstructieve aandoeningen van de luchtwegen, - bemrist breezhaler is indicated as a maintenance   treatment of asthma in adults and adolescents 12 years of age and older not adequately controlled with inhaled corticosteroids and inhaled short acting beta2-agonists.

Európska únia - holandčina - EMA (European Medicines Agency)

novartis europharm limited - glycopyrronium bromide, indacaterol (acetate), mometasone furoate - astma - geneesmiddelen voor obstructieve aandoeningen van de luchtwegen, - maintenance treatment of asthma in adults whose disease is not adequately controlled.

Európska únia - holandčina - EMA (European Medicines Agency)

novartis europharm limited - crizanlizumab - bloedarmoede, sikkelcel - other hematological agents - adakveo is indicated for the prevention of recurrent vaso occlusive crises (vocs) in sickle cell disease patients aged 16 years and older. it can be given as an add on therapy to hydroxyurea/hydroxycarbamide (hu/hc) or as monotherapy in patients for whom hu/hc is inappropriate or inadequate.

Európska únia - holandčina - EMA (European Medicines Agency)

novartis europharm limited - inclisiran - hypercholesterolemia; dyslipidemias - lipidemodificerende middelen - leqvio is indicated in adults with primary hypercholesterolaemia (heterozygous familial and non-familial) or mixed dyslipidaemia, as an adjunct to diet:in combination with a statin or statin with other lipid-lowering therapies in patients unable to reach ldl-c goals with the maximum tolerated dose of a statin, oralone or in combination with other lipid-lowering therapies in patients who are statin-intolerant, or for whom a statin is contraindicated.

Európska únia - holandčina - EMA (European Medicines Agency)

novartis ireland ltd - ofatumumab - multiple sclerose, relapsing-remitting - immunosuppressant - kesimpta is indicated for the treatment of adult patients with relapsing forms of multiple sclerosis (rms) with active disease defined by clinical or imaging features (see section 5.

Európska únia - holandčina - EMA (European Medicines Agency)

novartis europharm limited  - capmatinib dihydrochloride monohydrate - carcinoom, niet-kleincellige long - antineoplastische middelen - tabrecta as monotherapy is indicated for the treatment of adult patients with advanced non small cell lung cancer (nsclc) harbouring alterations leading to mesenchymal epithelial transition factor gene exon 14 (metex14) skipping, who require systemic therapy following prior treatment with immunotherapy and/or platinum based chemotherapy.

Holandsko - holandčina - CBG-MEB (College ter Beoordeling van Geneesmiddelen)

novartis pharma b.v. haaksbergweg 16 1101 bx amsterdam - everolimus 0,25 mg/stuk - tablet - butylhydroxytolueen (e 321) ; crospovidon (e 1202) ; hypromellose, type 2910 (3 - 15 mpa.s) (e 464) ; lactose 0-water ; lactose 1-water ; magnesiumstearaat (e 470b), - everolimus